Table 3 Duration and significance of differences between the panitumumab+BSC and BSC alone groups in Q-TWiST at varying utility weights

From: A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer

Utility per phase

Panitumumab+BSC vs BSC alone

TOX

TWiST

REL

Difference in Q-TWiST (weeks)

P- value

95% CI

0.00

1.00

0.00

5.25

<0.0001

2.90, 7.59

0.25

1.00

0.00

5.84

<0.0001

3.55, 8.13

0.50

1.00

0.00

6.43

<0.0001

4.15, 8.72

0.75

1.00

0.00

7.03

<0.0001

4.70, 9.36

1.00

1.00

0.00

7.62

<0.0001

5.20, 10.04

0.00

1.00

0.25

3.55

0.0020

1.30, 5.80

0.25

1.00

0.25

4.14

0.0002

1.97, 6.31

0.50

1.00

0.25

4.73

<0.0001

2.60, 6.87

0.75

1.00

0.25

5.33

<0.0001

3.17, 7.48

1.00

1.00

0.25

5.92

<0.0001

3.69, 8.15

0.00

1.00

0.50

1.84

0.1205

−0.48, 4.17

0.25

1.00

0.50

2.44

0.0316

0.21, 4.66

0.50

1.00

0.50

3.03

0.0061

0.86, 5.20

0.75

1.00

0.50

3.63

0.0010

1.46, 5.79

1.00

1.00

0.50

4.22

0.0002

2.01, 6.43

0.00

1.00

0.75

0.14

0.9124

−2.42, 2.71

0.25

1.00

0.75

0.74

0.5548

−1.71, 3.19

0.50

1.00

0.75

1.33

0.2716

−1.04, 3.70

0.75

1.00

0.75

1.92

0.1076

−0.42, 4.27

1.00

1.00

0.75

2.52

0.0369

0.15, 4.88

0.00

1.00

1.00

−1.56

0.2964

−4.48, 1.37

0.25

1.00

1.00

−0.96

0.5001

−3.76, 1.84

0.50

1.00

1.00

−0.37

0.7895

−3.08, 2.34

0.75

1.00

1.00

0.22

0.8693

−2.44, 2.89

1.00

1.00

1.00

0.82

0.5476

−1.85, 3.48

  1. Abbreviations: BSC=best supportive care; Q-TWiST=quality-adjusted time without symptoms of disease or toxicity of treatment; REL=relapse period until death or end of follow-up; TOX=days with ⩾grade 3 adverse events; TWiST=time without symptoms or toxicity.
Back to article page